» Articles » PMID: 23459007

Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies

Abstract

HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of resting memory CD4(+) T cells carrying latent but replication-competent viral genomes. Because strategies targeting this latent reservoir are now being tested in clinical trials, well-validated high-throughput assays that quantify this reservoir are urgently needed. Here we compare eleven different approaches for quantitating persistent HIV-1 in 30 patients on HAART, using the original viral outgrowth assay for resting CD4(+) T cells carrying inducible, replication-competent viral genomes as a standard for comparison. PCR-based assays for cells containing HIV-1 DNA gave infected cell frequencies at least 2 logs higher than the viral outgrowth assay, even in subjects who started HAART during acute/early infection. This difference may reflect defective viral genomes. The ratio of infected cell frequencies determined by viral outgrowth and PCR-based assays varied dramatically between patients. Although strong correlations with the viral outgrowth assay could not be formally excluded for most assays, correlations achieved statistical significance only for integrated HIV-1 DNA in peripheral blood mononuclear cells and HIV-1 RNA/DNA ratio in rectal CD4(+) T cells. Residual viremia was below the limit of detection in many subjects and did not correlate with the viral outgrowth assays. The dramatic differences in infected cell frequencies and the lack of a precise correlation between culture and PCR-based assays raise the possibility that the successful clearance of latently infected cells may be masked by a larger and variable pool of cells with defective proviruses. These defective proviruses are detected by PCR but may not be affected by reactivation strategies and may not require eradication to accomplish an effective cure. A molecular understanding of the discrepancy between infected cell frequencies measured by viral outgrowth versus PCR assays is an urgent priority in HIV-1 cure research.

Citing Articles

Bryostatin-1 enhances the proliferation and functionality of exhausted CD8+ T cells by upregulating MAP Kinase 11.

Li L, Zhao M, van Meurs M, Brouwers-Haspels I, den Dekker R, Wilmsen M Front Immunol. 2025; 15:1509874.

PMID: 39877358 PMC: 11772198. DOI: 10.3389/fimmu.2024.1509874.


Defective proviruses significantly impact viral transcription and immune activation in men and women with HIV-1 subtype C in rural South Africa.

Buchholtz N, Hermans L, Umunnakwe C, Nuhn M, Voss R, Need E Front Immunol. 2024; 15:1484358.

PMID: 39660138 PMC: 11628515. DOI: 10.3389/fimmu.2024.1484358.


Cognate antigen engagement induces HIV-1 expression in latently infected CD4 T cells from people on long-term antiretroviral therapy.

Moskovljevic M, Dragoni F, Board N, Wu F, Lai J, Zhang H Immunity. 2024; 57(12):2928-2944.e6.

PMID: 39612916 PMC: 11896817. DOI: 10.1016/j.immuni.2024.11.002.


Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.

Nel C, Frater J Front Immunol. 2024; 15:1478703.

PMID: 39575236 PMC: 11578998. DOI: 10.3389/fimmu.2024.1478703.


Rapid biphasic decay of intact and defective HIV DNA reservoir during acute treated HIV disease.

Barbehenn A, Shi L, Shao J, Hoh R, Hartig H, Pae V Nat Commun. 2024; 15(1):9966.

PMID: 39557853 PMC: 11574060. DOI: 10.1038/s41467-024-54116-1.


References
1.
Korin Y, Brooks D, Brown S, Korotzer A, Zack J . Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol. 2002; 76(16):8118-23. PMC: 155166. DOI: 10.1128/jvi.76.16.8118-8123.2002. View

2.
Bailey J, Sedaghat A, Kieffer T, Brennan T, Lee P, Wind-Rotolo M . Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006; 80(13):6441-57. PMC: 1488985. DOI: 10.1128/JVI.00591-06. View

3.
Chun T, Carruth L, Finzi D, Shen X, DiGiuseppe J, Taylor H . Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997; 387(6629):183-8. DOI: 10.1038/387183a0. View

4.
Archin N, Liberty A, Kashuba A, Choudhary S, Kuruc J, Crooks A . Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012; 487(7408):482-5. PMC: 3704185. DOI: 10.1038/nature11286. View

5.
Archin N, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis D . Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses. 2009; 25(2):207-12. PMC: 2853863. DOI: 10.1089/aid.2008.0191. View